Amgen (AMGN) Opens New Science And Innovation Center In Hyderabad
Article excerpt
Highlighted: the sentence this signal was extracted from
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Amgen (NasdaqGS:AMGN) announced the opening of a new Science and Innovation Center in Genome Valley, Hyderabad, expanding its global research and development presence. The Hyderabad center is designed to integrate scientific capabilities with data and digital tools to support discovery and development of new medicines. This expansion adds another research hub to Amgen's global footprint and increases its geographic diversification in Asia. Amgen is not the only healthcare stock investing in data driven research and development. It can be useful to compare this move with peers that are also building out their use of AI and digital tools in drug discovery through 44 healthcare AI stocks. Amgen is a large US biotech company with a reported market cap of about US$225.0b that focuses on discovering, developing, manufacturing, and delivering human therapeutics worldwide. For readers, this new Hyderabad center is part of Amgen's broader effort to expand its research and development footprint across global hubs. Beyond the headline: 1 risk and 4 things going right for Amgen that every investor should see. The Hyderabad Science and Innovation Center gives Amgen another hub to combine biology, data science, and digital tools in one place. For you, this points to a model that...
Keep reading with a free account
The rest of this article, and every signal for Amgen, is in your free account.
